Richard Schafer, DO
Family Medicine · Bristow, OKNPI 1164411526
Payments from drug & device makers
Across 267 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- AstraZeneca$880
- GSK$847
- Boehringer Ingelheim$655
- Lilly USA, LLC$484
- plus $2K from 21 others
What the payments were for
- Food & beverage$7,507100%
- Education$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 104 | $1,760 |
| Johnson & Johnson | 16 | $1,006 |
| AstraZeneca | 16 | $880 |
| GSK | 17 | $847 |
| Boehringer Ingelheim | 18 | $655 |
| Lilly USA, LLC | 19 | $484 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $404 |
| Novo Nordisk | 5 | $278 |
| Indivior Inc. | 9 | $238 |
| Teva Pharmaceuticals USA, Inc. | 4 | $172 |
| Pfizer | 6 | $165 |
| Astellas Pharma US Inc | 7 | $138 |
| Lundbeck LLC | 3 | $65 |
| Medtronic | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Smith+Nephew | 2 | $41 |
| UCB, Inc. | 2 | $36 |
| Exact Sciences | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $25 |
| Fortovia Therapeutics, Inc. | 1 | $23 |
| Biogen | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Optinose US, Inc. | 1 | $16 |
| Metacel Pharmaceuticals LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,537 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 199 | $159,595 |
| TrulicityDulaglutide | 102 | $115,200 |
| VraylarCariprazine Hcl | 64 | $103,225 |
| JardianceEmpagliflozin | 103 | $98,945 |
| OzempicSemaglutide | 72 | $94,964 |
| MounjaroTirzepatide | 85 | $94,254 |
| EliquisApixaban | 77 | $78,971 |
| LinzessLinaclotide | 62 | $52,706 |
| FarxigaDapagliflozin Propanediol | 38 | $49,759 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,111 | $37,565 |
| JanuviaSitagliptin Phosphate | 25 | $32,234 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $31,774 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 135 | $31,115 |
| GemtesaVibegron | 26 | $26,791 |
| Buprenorphine | 80 | $24,179 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $484 | $209,453187 claims |
| AbbVieVraylar, Linzess, Ubrelvy, Qulipta | $1,760 | $186,043154 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $847 | $176,668229 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $655 | $120,748144 claims |
| Novo NordiskOzempic | $278 | $94,96472 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $880 | $81,53379 claims |
| PfizerEliquis | $165 | $78,97177 claims |
| Johnson & JohnsonXarelto | $1,006 | $16,08319 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $28 | $15,34520 claims |
| Astellas Pharma US IncMyrbetriq | $138 | $11,51517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Bristow
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.